"Natalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
| Descriptor ID |
D000069442
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.813 D12.776.124.790.651.114.224.060.813 D12.776.377.715.548.114.224.200.813
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Natalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Natalizumab [D12.776.124.486.485.114.224.060.813]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Natalizumab [D12.776.124.790.651.114.224.060.813]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Natalizumab [D12.776.377.715.548.114.224.200.813]
Below are MeSH descriptors whose meaning is more specific than "Natalizumab".
This graph shows the total number of publications written about "Natalizumab" by people in this website by year, and whether "Natalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Natalizumab" by people in Profiles.
-
Gontika M, Skarlis C, Markoglou N, Tzanetakos D, Vakrakou A, Toulas P, Koutsis G, Evangelopoulos ME, Pons R, Dardiotis E, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M. Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions-a single-center retrospective observational study. Naunyn Schmiedebergs Arch Pharmacol. 2022 08; 395(8):933-943.
-
Gontika M, Skarlis C, Markoglou N, Evangelopoulos ME, Velonakis G, Chrousos GP, Dalakas M, Stefanis L, Anagnostouli M. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurol Sci. 2022 Apr; 43(4):2641-2649.
-
Kekre N, Kim HT, Hofer J, Ho VT, Koreth J, Armand P, Nikiforow S, Gooptu M, Romee R, Alyea EP, Nageshwar P, Glotzbecker B, El-Jawahri A, DeFilipp Z, Soiffer RJ, Antin JH, Chen YB, Cutler C. Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012.
-
Shivashankar R, Pardi DS. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):589-601.
-
Bourre B, Gueudry J, Lefaucheur R, Borden A, Malt?te D, Patel SS, Van Tassel SH, Gupta MP, Orlin A, Nealon NM. Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab. Neurology. 2016 Jan 19; 86(3):312-3.
-
Crossley KM, Agnihotri S, Chaganti J, Rodriguez ML, McNally LP, Venna N, Turbett SE, Gutman M, Morey A, Koralnik IJ, Brew BJ. Recurrence of progressive multifocal leukoencephalopathy despite immune recovery in two HIV seropositive individuals. J Neurovirol. 2016 08; 22(4):541-5.
-
Van Tassel SH, Gupta MP, Orlin A, Nealon NM, Patel SS. Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab. Neurology. 2015 May 26; 84(21):2198-9.
-
Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006 Dec; 35(4):757-73.